- Home
- ARCT vs KROS Comparison
ARCT vs KROS Comparison
Compare ARCT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- KROS
- Stock Information
- Founded
- ARCT 2013
- KROS 2015
- Country
- ARCT United States
- KROS United States
- Employees
- ARCT N/A
- KROS N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- KROS Health Care
- Exchange
- ARCT Nasdaq
- KROS Nasdaq
- Market Cap
- ARCT 487.0M
- KROS 460.6M
- IPO Year
- ARCT N/A
- KROS 2020
- Fundamental
- Price
- ARCT $16.36
- KROS $11.03
- Analyst Decision
- ARCT Strong Buy
- KROS Buy
- Analyst Count
- ARCT 8
- KROS 11
- Target Price
- ARCT $61.00
- KROS $45.33
- AVG Volume (30 Days)
- ARCT 405.9K
- KROS 2.1M
- Earning Date
- ARCT 03-06-2025
- KROS 02-26-2025
- Dividend Yield
- ARCT N/A
- KROS N/A
- EPS Growth
- ARCT N/A
- KROS N/A
- EPS
- ARCT N/A
- KROS N/A
- Revenue
- ARCT $160,399,000.00
- KROS $651,000.00
- Revenue This Year
- ARCT $7.33
- KROS $303.27
- Revenue Next Year
- ARCT $4.71
- KROS N/A
- P/E Ratio
- ARCT N/A
- KROS N/A
- Revenue Growth
- ARCT N/A
- KROS 8037.50
- 52 Week Low
- ARCT $14.30
- KROS $9.78
- 52 Week High
- ARCT $45.00
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- ARCT 45.85
- KROS 25.01
- Support Level
- ARCT $15.34
- KROS $11.04
- Resistance Level
- ARCT $17.95
- KROS $11.36
- Average True Range (ATR)
- ARCT 1.17
- KROS 0.53
- MACD
- ARCT -0.08
- KROS 1.15
- Stochastic Oscillator
- ARCT 39.08
- KROS 37.80
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.